Controller medications, also known as daily maintenance medications, are a critical tool for managing asthma — reducing daily ...

After many trips to the doctor's office, five-year-old Burton Hayes's asthma was finally under control with a medication ...

It is one of GSK's top drugs, with sales of $2.2 billion last ... "Today's data, along with recent phase III data in severe asthma, will be used in regulatory filings around the world." ...

GSK plc GSK announced ... 2 studies showed that treatment with depemokimab resulted in statistically significant and clinically meaningful reductions in exacerbations (asthma attacks) over 52 ...

Two of GSK Plc’s blockbuster vaccines delivered lower than expected sales in the third quarter after the British drugmaker ...

Six months after Amgen and AstraZeneca reported promising results for Tezspire (t | A phase 3 study has shown that ...

The first phase III trials in severe asthma, SWIFT-1 and SWIFT-2, have been reported and published in the New England Journal of Medicine. GSK continues to build on decades of pioneering work to ...